Industry news that matters to you.  Learn more

Quest Diagnostics Launches New Molecular Test Panel for Enhanced Thyroid Cancer Detection

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal. The test is believed to be the most comprehensive panel clinically available to identify mutations associated with four gene markers indicated by the American Thyroid Association for the clinical management of indeterminate thyroid biopsies.

Rapid Technique Developed for Diagnosing Papillary Thyroid Cancer During Surgery

During surgical removal of thyroid tissue suspicious for cancer, fast, reliable, and cost-effective techniques are needed to analyze the resected tissue for biomarker — including BRAF V600E, a molecular biomarker for papillary thyroid cancer (PTC) — that can confirm the presence and type of cancer cells. Researchers have developed a new, rapid method for direct detection of the BRAF V600E gene in thyroid tissue without the need to purify DNA from tumor cells — high resolution melting analysis (HRM).